{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T18:05:40Z","timestamp":1791309940310,"version":"4.3.1"},"reference-count":49,"publisher":"American Association for Cancer Research (AACR)","issue":"8","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2009,4,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Waldenstro\u0308m's macroglobulinemia (WM) is a distinct clinicobiological entity defined as a B-cell neoplasm characterized by a lymphoplasmacytic infiltrate in bone marrow (BM) and IgM paraprotein production. Cytogenetic analyses were historically limited by difficulty in obtaining tumor metaphases, and the genetic basis of the disease remains poorly defined. Here, we performed a comprehensive analysis in 42 WM patients by using a high-resolution, array-based comparative genomic hybridization approach to unravel the genetic mechanisms associated with WM pathogenesis. Overall, 83% of cases have chromosomal abnormalities, with a median of three abnormalities per patient. Gain of 6p was the second most common abnormality (17%), and its presence was always concomitant with 6q loss. A minimal deleted region, including MIRN15A and MIRN16-1, was delineated on 13q14 in 10% of patients. Of interest, we reported biallelic deletions and\/or inactivating mutations with uniparental disomy in tumor necrosis factor (TNF) receptor\u2013associated factor 3 and TNF\u03b1-induced protein 3, two negative regulators of the nuclear factor-\u03baB (NF-\u03baB) signaling pathway. Furthermore, we confirmed the association between TRAF3 inactivation and increased transcriptional activity of NF-\u03baB target genes. Mutational activation of the NF-\u03baB pathway, which is normally activated by ligand receptor interactions within the BM microenvironment, highlights its biological importance, and suggests a therapeutic role for inhibitors of NF-\u03baB pathway activation in the treatment of WM. [Cancer Res 2009;69(8):3579\u201388]<\/jats:p>","DOI":"10.1158\/0008-5472.can-08-3701","type":"journal-article","created":{"date-parts":[[2009,4,7]],"date-time":"2009-04-07T22:38:58Z","timestamp":1239143938000},"page":"3579-3588","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":138,"title":["Identification of Copy Number Abnormalities and Inactivating Mutations in Two Negative Regulators of Nuclear Factor-\u03baB Signaling Pathways in Waldenstro\u0308m's Macroglobulinemia"],"prefix":"10.1158","volume":"69","author":[{"given":"Esteban","family":"Braggio","sequence":"first","affiliation":[{"name":"1Mayo Clinic, Scottsdale, Arizona;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan J.","family":"Keats","sequence":"additional","affiliation":[{"name":"1Mayo Clinic, Scottsdale, Arizona;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Leleu","sequence":"additional","affiliation":[{"name":"2Dana-Farber Cancer Institute, Boston, Massachusetts;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Van Wier","sequence":"additional","affiliation":[{"name":"1Mayo Clinic, Scottsdale, Arizona;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor H.","family":"Jimenez-Zepeda","sequence":"additional","affiliation":[{"name":"1Mayo Clinic, Scottsdale, Arizona;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Valdez","sequence":"additional","affiliation":[{"name":"1Mayo Clinic, Scottsdale, Arizona;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roelandt F.J.","family":"Schop","sequence":"additional","affiliation":[{"name":"1Mayo Clinic, Scottsdale, Arizona;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tammy","family":"Price-Troska","sequence":"additional","affiliation":[{"name":"3Mayo Clinic, Rochester, Minnesota; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Henderson","sequence":"additional","affiliation":[{"name":"3Mayo Clinic, Rochester, Minnesota; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Sacco","sequence":"additional","affiliation":[{"name":"2Dana-Farber Cancer Institute, Boston, Massachusetts;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feda","family":"Azab","sequence":"additional","affiliation":[{"name":"2Dana-Farber Cancer Institute, Boston, Massachusetts;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Greipp","sequence":"additional","affiliation":[{"name":"3Mayo Clinic, Rochester, Minnesota; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morie","family":"Gertz","sequence":"additional","affiliation":[{"name":"3Mayo Clinic, Rochester, Minnesota; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Hayman","sequence":"additional","affiliation":[{"name":"3Mayo Clinic, Rochester, Minnesota; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Vincent","family":"Rajkumar","sequence":"additional","affiliation":[{"name":"3Mayo Clinic, Rochester, Minnesota; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Carpten","sequence":"additional","affiliation":[{"name":"4Translational Genomics, Phoenix, Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Chesi","sequence":"additional","affiliation":[{"name":"1Mayo Clinic, Scottsdale, Arizona;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Barrett","sequence":"additional","affiliation":[{"name":"4Translational Genomics, Phoenix, Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Keith","family":"Stewart","sequence":"additional","affiliation":[{"name":"1Mayo Clinic, Scottsdale, Arizona;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet","family":"Dogan","sequence":"additional","affiliation":[{"name":"3Mayo Clinic, Rochester, Minnesota; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Leif","family":"Bergsagel","sequence":"additional","affiliation":[{"name":"1Mayo Clinic, Scottsdale, Arizona;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene M.","family":"Ghobrial","sequence":"additional","affiliation":[{"name":"2Dana-Farber Cancer Institute, Boston, Massachusetts;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Fonseca","sequence":"additional","affiliation":[{"name":"1Mayo Clinic, Scottsdale, Arizona;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2009,4,15]]},"reference":[{"key":"2022061701485649700_B1","doi-asserted-by":"crossref","unstructured":"Fonseca R, Hayman S. Waldenstro\u0308m macroglobulinaemia. Br J Haematol\u20082007; 138: 700\u201320.","DOI":"10.1111\/j.1365-2141.2007.06724.x"},{"key":"2022061701485649700_B2","doi-asserted-by":"crossref","unstructured":"McMaster ML. Familial Waldenstro\u0308m's macroglobulinemia. Semin Oncol\u20082003; 30: 146\u201352.","DOI":"10.1053\/sonc.2003.50063"},{"key":"2022061701485649700_B3","doi-asserted-by":"crossref","unstructured":"McMaster ML, Goldin LR, Bai Y, et al. Genomewide linkage screen for Waldenstro\u0308m's macroglobulinemia susceptibility loci in high-risk families. Am J Hum Genet\u20082006; 79: 695\u2013701.","DOI":"10.1086\/507687"},{"key":"2022061701485649700_B4","doi-asserted-by":"crossref","unstructured":"Schop RF, Kuehl M, Van Wier SA, et al. Waldenstro\u0308m macroglobulinemia neoplastic cells lack immunoglobulin heavy chain locus translocations but have frequent 6q deletions. Blood\u20082002; 100: 2996\u20133001.","DOI":"10.1182\/blood.V100.8.2996"},{"key":"2022061701485649700_B5","doi-asserted-by":"crossref","unstructured":"Terre C, Nguyen-Khac F, Barin C, et al. Trisomy 4, a new chromosomal abnormality in Waldenstro\u0308m's macroglobulinemia: a study of 39 cases. Leukemia\u20082006; 20: 1634\u20136.","DOI":"10.1038\/sj.leu.2404314"},{"key":"2022061701485649700_B6","doi-asserted-by":"crossref","unstructured":"Schop RF, Jalal SM, Van Wier SA, et al. Deletions of 17p13.1 and 13q14 are uncommon in Waldenstro\u0308m macroglobulinemia clonal cells and mostly seen at the time of disease progression. Cancer Genet Cytogenet\u20082002; 132: 55\u201360.","DOI":"10.1016\/S0165-4608(01)00526-X"},{"key":"2022061701485649700_B7","doi-asserted-by":"crossref","unstructured":"Hayden MS, Gosh S. Signaling to NF-\u03baB. Genes Dev\u20082004; 18: 2195\u2013224.","DOI":"10.1101\/gad.1228704"},{"key":"2022061701485649700_B8","doi-asserted-by":"crossref","unstructured":"Ghosh S, Karin M. Missing pieces in the NF-\u03baB puzzle. Cell\u20082002; 109: S81\u201396.","DOI":"10.1016\/S0092-8674(02)00703-1"},{"key":"2022061701485649700_B9","doi-asserted-by":"crossref","unstructured":"Senftleben U, Cao Y, Xiao G, et al. Activation by IKK\u03b1 of a second, evolutionary conserved, NF-\u03ba B signaling pathway. Science\u20082001; 293: 1495\u20139.","DOI":"10.1126\/science.1062677"},{"key":"2022061701485649700_B10","doi-asserted-by":"crossref","unstructured":"Basseres DS, Baldwin A. Nuclear factor-\u03baB and inhibitor of kB kinase pathways in oncogenic initiation and progression. Oncogene\u20082006; 25: 6817\u201330.","DOI":"10.1038\/sj.onc.1209942"},{"key":"2022061701485649700_B11","doi-asserted-by":"crossref","unstructured":"Courtois G, Gilmore T. Mutations in the NF-\u03baB signaling pathway: implications for human disease. Oncogene\u20082006; 25: 6831\u201343.","DOI":"10.1038\/sj.onc.1209939"},{"key":"2022061701485649700_B12","doi-asserted-by":"crossref","unstructured":"Keats JJ, Fonseca R, Chesi M, et al. Promiscuous mutations activate the noncanonical NF-\u03baB pathway in multiple myeloma. Cancer Cell\u20082007; 12: 131\u201344.","DOI":"10.1016\/j.ccr.2007.07.003"},{"key":"2022061701485649700_B13","doi-asserted-by":"crossref","unstructured":"Annunziata CM, Davies R, Demchenko Y, et al. Frequent engagement of the classical and alternative NF-\u03baB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell\u20082007; 12: 115\u201330.","DOI":"10.1016\/j.ccr.2007.07.004"},{"key":"2022061701485649700_B14","doi-asserted-by":"crossref","unstructured":"Lenz G, Wright GW, Emre NC, et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci U S A\u20082008; 105: 13520\u20135.","DOI":"10.1073\/pnas.0804295105"},{"key":"2022061701485649700_B15","doi-asserted-by":"crossref","unstructured":"Lucas PC, Yonezumi M, Inohara N, et al. Bcl10 and MALT1, independent targets of chromosomal translocation in malt lymphoma, cooperate in a novel NF-\u03baB signaling pathway. J Biol Chem\u20082001; 276: 19012\u20139.","DOI":"10.1074\/jbc.M009984200"},{"key":"2022061701485649700_B16","unstructured":"Morgan JA, Yin Y, Borowsky AD, et al. Breakpoints of the t(11;18)(q21;q21) in mucosa-associated lymphoid tissue (MALT) lymphoma lie within or near the previously undescribed gene MALT1 in chromosome 18. Cancer Res\u20081999; 59: 6205\u201313."},{"key":"2022061701485649700_B17","doi-asserted-by":"crossref","unstructured":"Lipson D, Aumann Y, Ben-Dor A, Linial N, Yakhini Z. Efficient calculation of interval scores for DNA copy number data analysis. J Comput Biol\u20082006; 13: 215\u201328.","DOI":"10.1089\/cmb.2006.13.215"},{"key":"2022061701485649700_B18","doi-asserted-by":"crossref","unstructured":"de Smith AJ, Tsalenko A, Sampas N, et al. Array CGH analysis of copy number variation identifies 1284 new genes variant in healthy White males: implications for association studies of complex diseases. Hum Mol Genet\u20082007; 16: 2783\u201394.","DOI":"10.1093\/hmg\/ddm208"},{"key":"2022061701485649700_B19","doi-asserted-by":"crossref","unstructured":"Ahmann GJ, Jalal SM, Juneau AL, et al. A novel three-color, clone-specific fluorescence in situ hybridization procedure for monoclonal gammopathies. Cancer Genet Cytogenet\u20081998; 101: 7\u201311.","DOI":"10.1016\/S0165-4608(97)00058-7"},{"key":"2022061701485649700_B20","doi-asserted-by":"crossref","unstructured":"Chng WJ, Schop R, Price-Troska T, et al. Gene-expression profiling of Waldenstrom macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma. Blood\u20082006; 108: 2755\u201363.","DOI":"10.1182\/blood-2006-02-005488"},{"key":"2022061701485649700_B21","doi-asserted-by":"crossref","unstructured":"Pasqualucci L, Compagno M, Houldsworth J, et al. Inactivation of the PRDM1\/BLIMP1 gene in diffuse large B cell lymphoma. J Exp Med\u20082006; 203: 311\u20137.","DOI":"10.1084\/jem.20052204"},{"key":"2022061701485649700_B22","doi-asserted-by":"crossref","unstructured":"Honma K, Tsuzuki S, Nakagawa M, et al. TNFAIP3 is the target gene of chromosome band 6q23.3-q24.1 loss in ocular adnexal marginal zone B cell lymphoma. Genes Chromosomes Cancer\u20082008; 47: 1\u20137.","DOI":"10.1002\/gcc.20499"},{"key":"2022061701485649700_B23","doi-asserted-by":"crossref","unstructured":"Thelander EF, Ichimura K, Corcoran M, et al. Characterization of 6q deletions in mature B cell lymphomas and childhood acute lymphoblastic leukemia. Leuk Lymphoma\u20082008; 49: 477\u201387.","DOI":"10.1080\/10428190701817282"},{"key":"2022061701485649700_B24","doi-asserted-by":"crossref","unstructured":"Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A\u20082002; 99: 15524\u20139.","DOI":"10.1073\/pnas.242606799"},{"key":"2022061701485649700_B25","doi-asserted-by":"crossref","unstructured":"Liao G, Zhang M, Harhaj EW, Sun SC. Regulation of the NF-\u03baB-inducing kinase by tumor necrosis factor receptor-associated factor 3-induced degradation. J Biol Chem\u20082004; 279: 26243\u201350.","DOI":"10.1074\/jbc.M403286200"},{"key":"2022061701485649700_B26","doi-asserted-by":"crossref","unstructured":"Ni CZ, Oganesyan G, Welsh K, et al. Key molecular contacts promote recognition of the BAFF receptor by TNF receptor-associated factor 3: implications for intracellular signaling regulation. J Immunol\u20082004; 173: 7394\u2013400.","DOI":"10.4049\/jimmunol.173.12.7394"},{"key":"2022061701485649700_B27","doi-asserted-by":"crossref","unstructured":"Nutt SL, Heavey B, Rolink AG, Busslinger M. Commitment to the B-lymphoid lineage depends on the transcription factor Pax5. Nature\u20081999; 401: 556\u201362.","DOI":"10.1038\/44076"},{"key":"2022061701485649700_B28","doi-asserted-by":"crossref","unstructured":"Iida S, Rao PH, Nallasivam P, et al. The t(9;14)(p13;q32) chromosomal translocation associated with lymphoplasmacytoid lymphoma involves the PAX-5 gene. Blood\u20081996; 88: 4110\u20137.","DOI":"10.1182\/blood.V88.11.4110.4110"},{"key":"2022061701485649700_B29","doi-asserted-by":"crossref","unstructured":"Dierlamm J, Pittaluga S, Wlodarska I, et al. Marginal zone B-cell lymphomas of different sites share similar cytogenetic and morphologic features. Blood\u20081996; 87: 299\u2013307.","DOI":"10.1182\/blood.V87.1.299.299"},{"key":"2022061701485649700_B30","doi-asserted-by":"crossref","unstructured":"Karhu R, Knuutila S, Kallioniemi OP, et al. Frequent loss of the 11q14\u201324 region in chronic lymphocytic leukemia: a study by comparative genomic hybridization. Tampere CLL Group. Genes Chromosomes Cancer\u20081997; 19: 286\u201390.","DOI":"10.1002\/(SICI)1098-2264(199708)19:4<286::AID-GCC12>3.0.CO;2-E"},{"key":"2022061701485649700_B31","doi-asserted-by":"crossref","unstructured":"Sole F, Woessner S, Perez-Losada A, et al. Cytogenetic studies in seventy-six cases of B-chronic lymphoproliferative disorders. Cancer Genet Cytogenet\u20081997; 93: 160\u20136.","DOI":"10.1016\/S0165-4608(96)00191-4"},{"key":"2022061701485649700_B32","doi-asserted-by":"crossref","unstructured":"Fonseca R, Oken MM, Harrington D, et al. Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q arm or monosomy. Leukemia\u20082001; 15: 981\u20136.","DOI":"10.1038\/sj.leu.2402125"},{"key":"2022061701485649700_B33","doi-asserted-by":"crossref","unstructured":"Calin GA, Cimmino A, Fabbri M, et al. MiR-15a and miR-16\u20131 cluster functions in human leukemia. Proc Natl Acad Sci U S A\u20082008; 105: 5166\u201371.","DOI":"10.1073\/pnas.0800121105"},{"key":"2022061701485649700_B34","doi-asserted-by":"crossref","unstructured":"Cimmino A, Calin GA, Fabbri M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A\u20082005; 102: 13944\u20139.","DOI":"10.1073\/pnas.0506654102"},{"key":"2022061701485649700_B35","doi-asserted-by":"crossref","unstructured":"Ferreira BI, Garci\u0301a JF, Suela J, et al. Comparative genome profiling across subtypes of low-grade B-cell lymphoma identifies type-specific and common aberrations that target genes with a role in B-cell neoplasia. Haematologica\u20082008; 93: 670\u20139.","DOI":"10.3324\/haematol.12221"},{"key":"2022061701485649700_B36","doi-asserted-by":"crossref","unstructured":"Hauer J, Pu\u0308schner S, Ramakrishnan P, et al. TNF receptor (TNFR)-associated factor (TRAF) 3 serves as an inhibitor of TRAF2\/5-mediated activation of the noncanonical NF-\u03baB pathway by TRAF-binding TNFRs. Proc Natl Acad Sci U S A\u20082005; 102: 2874\u20139.","DOI":"10.1073\/pnas.0500187102"},{"key":"2022061701485649700_B37","doi-asserted-by":"crossref","unstructured":"He JQ, Zarnegar B, Oganesyan G, et al. Rescue of TRAF3-null mice by p100 NF-\u03baB deficiency. J Exp Med\u20082006; 203: 2413\u20138.","DOI":"10.1084\/jem.20061166"},{"key":"2022061701485649700_B38","doi-asserted-by":"crossref","unstructured":"Xie P, Stunz L, Larison KD, Yang B, Bishop GA. Tumor necrosis factor receptor-associated factor 3 is a critical regulator of B cell homeostasis in secondary lymphoid organs. Immunity\u20082007; 27: 253\u201367.","DOI":"10.1016\/j.immuni.2007.07.012"},{"key":"2022061701485649700_B39","doi-asserted-by":"crossref","unstructured":"Boone DL, Turer EE, Lee EG, et al. The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses. Nat Immunol\u20082004; 5: 1052\u201360.","DOI":"10.1038\/ni1110"},{"key":"2022061701485649700_B40","doi-asserted-by":"crossref","unstructured":"Wang YY, Li L, Han KJ, Zhai Z, Shu HB. A20 is a potent inhibitor of TLR3- and Sendai virus-induced activation of NF-\u03baB and ISRE and IFN-\u03b2 promoter. FEBS Lett\u20082004; 576: 86\u201390.","DOI":"10.1016\/j.febslet.2004.08.071"},{"key":"2022061701485649700_B41","doi-asserted-by":"crossref","unstructured":"Lee EG, Boone DL, Chai S, et al. Failure to regulate TNF-induced NF-\u03baB and cell death responses in A20-deficient mice. Science\u20082000; 289: 2350\u20134.","DOI":"10.1126\/science.289.5488.2350"},{"key":"2022061701485649700_B42","doi-asserted-by":"crossref","unstructured":"Graham RR, Cotsapas C, Davies L, et al. Genetic variants near TNFAIP3 on 6q23 are associated with systemic lupus erythematosus. Nat Genet 2008;Aug 1 [Epub ahead of print].","DOI":"10.1038\/ng.200"},{"key":"2022061701485649700_B43","doi-asserted-by":"crossref","unstructured":"Musone SL, Taylor KE, Lu TT, et al. Multiple polymorphisms in the TNFAIP3 region are independently associated with systemic lupus erythematosus. Nat Genet 2008;Aug 1 [Epub ahead of print].","DOI":"10.1038\/ng.202"},{"key":"2022061701485649700_B44","doi-asserted-by":"crossref","unstructured":"Plenge RM, Cotsapas C, Davies L, et al. Two independent alleles at 6q23 associated with risk of rheumatoid arthritis. Nat Genet\u20082007; 39: 1477\u201382.","DOI":"10.1038\/ng.2007.27"},{"key":"2022061701485649700_B45","doi-asserted-by":"crossref","unstructured":"Wolfrum S, Teupser D, Tan M, Chen KY, Breslow JL. The protective effect of A20 on atherosclerosis in apolipoprotein E-deficient mice is associated with reduced expression of NF-\u03baB target genes. Proc Natl Acad Sci U S A\u20082007; 104: 18601\u20136.","DOI":"10.1073\/pnas.0709011104"},{"key":"2022061701485649700_B46","doi-asserted-by":"crossref","unstructured":"Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med\u20082003; 348: 2609\u201317.","DOI":"10.1056\/NEJMoa030288"},{"key":"2022061701485649700_B47","doi-asserted-by":"crossref","unstructured":"Chen CI, Kouroukis C, White D, et al. Bortezomib is active in patients with untreated or relapsed Waldenstro\u0308m's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol\u20082007; 25: 1570\u20135.","DOI":"10.1200\/JCO.2006.07.8659"},{"key":"2022061701485649700_B48","doi-asserted-by":"crossref","unstructured":"Leleu X, Eeckhoute J, Jia X, et al. Targeting NF-\u03baB in Waldenstro\u0308m macroglobulinemia. Blood\u20082008; 111: 5068\u201377.","DOI":"10.1182\/blood-2007-09-115170"},{"key":"2022061701485649700_B49","doi-asserted-by":"crossref","unstructured":"Treon SP, Hunter Z, Matous J, et al. Multicenter clinical trial of bortezomib in relapsed\/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248. Clin Cancer Res\u20082007; 13: 3320\u20135.","DOI":"10.1158\/1078-0432.CCR-06-2511"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/69\/8\/3579\/2623802\/3579.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/69\/8\/3579\/2623802\/3579.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T05:20:30Z","timestamp":1655443230000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/69\/8\/3579\/553325\/Identification-of-Copy-Number-Abnormalities-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4,15]]},"references-count":49,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2009,4,15]]},"published-print":{"date-parts":[[2009,4,15]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-08-3701","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.22381452.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22381455","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22381446","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22381467","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22381473","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22381461","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22381446.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22381452","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22381464","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22381449.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22381473.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22381455.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22381458","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6499872","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6499872.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22381449","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22381464.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22381458.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22381470.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22381461.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22381467.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22381470","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,4,15]]}}}